精密醫療的共同研究·授權契約(2019年～2025年)

Precision Medicine Collaboration and Licensing Deals 2019-2025

出版日期: 2025年05月01日 | 出版商:

Current Partnering | 英文 650+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球生物醫藥品產業調查分析，2019年～2025年約1,221件相關的精密醫療的共同研究·授權契約，契約條件等詳細資訊。

簡介
過去數年的精密醫療契約
最活躍的精密醫療談判者
精密醫療契約:各類型契約
精密醫療契約:各治療領域
精密醫療契約:各產品部門
精密醫療契約的契約條件
- 精密醫療契約的標題金額
- 精密醫療契約的預付款
- 精密醫療契約的階段性付款
- 精密醫療的權利金費率

第3章主要精密醫療契約

簡介
前幾名的精密醫療契約(金額)

第4章最活躍的精密醫療談判者

簡介
最活躍的精密醫療談判者
最活躍的精密醫療契約企業的簡介

第5章精密醫療契約名錄

簡介
精密醫療契約名錄

第6章精密醫療的契約:各技術類型

契約名錄
契約名錄 - 精密醫療契約:各企業(A-Z)
契約名錄 - 精密醫療契約:各類型契約
契約名錄 - 精密醫療契約:各治療領域
契約類型定義
關於Biopharma Research Ltd
Current Partnering
Current Agreements
Current Partnering近幾年的報告標題

簡介目錄

Product Code: CP2108

Precision Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1221 precision medicine deals announced since 2019 including financial terms where available including links to online deal records of actual precision medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine dealmaking since 2019.

Chapter 3 provides an overview of the leading precision medicine deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine dealmaking with a brief summary followed by a comprehensive listing of precision medicine deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine partnering deals signed and announced since Jan 2019. The chapter is organized by specific precision medicine technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse precision medicine collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Precision Medicine Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine Collaboration and Licensing Deals includes:

Trends in precision medicine dealmaking in the biopharma industry
Directory of precision medicine deal records covering pharmaceutical and biotechnology
The leading precision medicine deals by value
Most active precision medicine licensing dealmakers
Precision Medicine Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine dealmaking

2.1. Introduction
2.2. Precision medicine deals over the years
2.3. Most active precision medicine dealmakers
2.4. Precision medicine deals by deal type
2.5. Precision medicine deals by therapy area
2.6. Precision medicine deals by industry sector
2.7. Deal terms for precision medicine deals
- 2.7.1 Precision medicine deals headline values
- 2.7.2 Precision medicine deal upfront payments
- 2.7.3 Precision medicine deal milestone payments
- 2.7.4 Precision medicine royalty rates